Is a 'Fire Sale' in Store for Valeant Pharma (VRX)?

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/21/2026

1. INTC
2. DSX
3. GNK
4. DAL
5. AWK
6. SPCX
7. III
8. TTEC
9. SNY

Go back to Is a 'Fire Sale' in Store for Valeant Pharma (VRX)?

Valeant (VRX) Price Target Cut to $195 at Guggenheim; Thesis Intact

November 6, 2015 6:29 AM EST

Guggenheim analyst Louise Chen lowered her price target on Valeant Pharmaceuticals (NYSE: VRX) to $195.00 (from $300.00) but maintained a Buy rating saying the investment thesis remains intact.

Chen commented, "We are lowering our PT for VRX to $195 from $300. The decrease in our PT is... More

Worst Case Valeant (VRX) is a Buy - Mizuho

November 5, 2015 3:13 PM EST

Mizuho Securities analyst Irina Koffler said worse case analysis and Valeant Pharmaceuticals (NYSE: VRX) is a Buy. The firm reiterated a Buy rating and $155 price target.

The stock is no longer trading on fundamentals in our view. We look at a liquidation valuation in the extreme case that management is ousted and the business is put up for sale under distressed conditions. We conclude shares are undervalued and reiterate our BUY rating

Key points:

We try to remain rational and reiterate our BUY rating: We understand the... More

Ackman, in email, says supports Valeant CEO Pearson

November 5, 2015 2:43 PM EST

BOSTON (Reuters) - Billionaire investor William Ackman on Thursday told Valeant Pharmaceuticals International Inc's (NYSE: VRX)(NYSE: VRX) chief executive that he supports him and praised management and the board of directors for considering "any and all alternatives" that would... More